Observation on the efficacy of Etiasa in combined with mesalazine suppository in the treatment of ulcerative colitis

Observation on the efficacy of Etiasa in combined with mesalazine suppository in the treatment of ulcerative colitis

Objective: To analyze the clinical effect of Etiasa (mesalazine slow-release granules) in combined with mesalazine suppository in the treatment of ulcerative colitis and the medication safety. Methods: A total of 82 patients with ulcerative colitis who were admitted in our hospital from June, 201...

Full description

Bibliographic Details
Main Authors:	Min Zhao, Chang-Ye Sang, Zhen-Jun Wang, Yan-Chun Xu
Format:	Article
Language:	English
Published:	Editorial Board of Journal of Hainan Medical University 2016-06-01
Series:	Journal of Hainan Medical University
Subjects:	Mesalazine slow-release granules Mesalazine suppository Ulcerative colitis Efficacy evaluation Safety
Online Access:	http://www.hnykdxxb.com/PDF/201612/17.pdf

Similar Items

DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET
by: Alvaro Mitsunori NISHIKAWA, et al.

Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis
by: Myoungrin Park, et al.
Published: (2019-04-01)

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
by: Yoshinori Arai, et al.
Published: (2011-10-01)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)

Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis
by: Satohiro Matsumoto, et al.
Published: (2016-05-01)

Mesalazin-induced eosinophilic pneumonia in a 15-year-old boy with ulcerative colitis
by: G. N. Yankinа, et al.
Published: (2019-10-01)

What is the real-life maintenance mesalazine dose in ulcerative colitis?
by: Alicia Algaba, et al.

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2018-04-01)

The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice
by: O. V. Knyazev, et al.
Published: (2019-10-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

Clinical effect and effect of Mesalazine combined with Bifico on oxidatives stress and cytokines in patients with ulcerative colitis
by: Zhi-Gang Huang, et al.
Published: (2016-03-01)

Clinical and economic efficiency of multi-matrix mesalazine in ulcerative colitis treatment in the healthcare system of the Republic of Kazakhstan
by: Alima Almadiyeva, et al.
Published: (2019-06-01)

Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
by: Mittendorf Thomas, et al.
Published: (2011-07-01)

Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis
by: Rong Li, et al.
Published: (2021-08-01)

THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE
by: O. V. Knyazev, et al.
Published: (2018-01-01)

Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis
by: Haotian Chen, et al.
Published: (2021-06-01)

Mesalazine-induced myocarditis: a case report
by: Shiva T. Radhakrishnan, et al.
Published: (2018-02-01)

SOME ASPECTS OF TREATMENT FOR LEFT-SIDED ULCERATIVE COLITIS
by: P. A. Makarchuk, et al.
Published: (2016-02-01)

Therapeutic effectiveness of rectally administered fish oil and mesalazine in trinitrobenzenesulfonic acid-induced colitis
by: Elif Yorulmaz, et al.
Published: (2019-10-01)

Mesalazine-induced Hypersensitivity Pneumonitis
by: Ana Pereira, et al.
Published: (2021-01-01)

Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
by: Qian-Zhang Ma, et al.
Published: (2019-06-01)

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES
by: M. V. Shapina, et al.
Published: (2017-11-01)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
by: Jalal Asadi, et al.
Published: (2017-12-01)

Lung disease/pneumonitis in a patient with ulcerative colitis due to mesalazine
by: O. A. Sablin, et al.
Published: (2021-02-01)

Effect of mesalazine combined with tanshinone on inflammatory cytokines and hypercoagulation status in patients with ulcerative colitis
by: De-Shan Xiong, et al.
Published: (2016-11-01)

Mesalazine-induced eosinophilic pneumonia with bone marrow infiltration: a case report and literature review
by: Zhang Y, et al.
Published: (2016-06-01)

Spectrophotometric Determination of Mesalazine Via Arsenazo III- Cerium(III) Reaction
by: Zeena Z. Al-Abdaly
Published: (2011-03-01)

A retrospective study on a cohort of patients with lymphocytic colitis Estudio retrospectivo de una cohorte de pacientes con colitis linfocítica
by: D. Simondi, et al.
Published: (2010-06-01)

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach
by: Silvio Danese, et al.
Published: (2018-10-01)

PHARMACOECONOMIC EVLUATION OF 5-ASA APPLICATION IN LIGHT AND MEDIUM GRAVE DISSEMINATED (RECURRING) ULCERATIVE COLITIS
by: P. A. Balunov
Published: (2017-11-01)

Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora
by: Zhengjun Wang, et al.
Published: (2021-01-01)

Application of 5-Aminosalicylic Acid Preparations in the Treatment of Inflammatory Bowel Diseases
by: Yu.M. Stepanov, et al.
Published: (2016-09-01)

Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials
by: Yi-ming Chen, et al.
Published: (2020-05-01)

Preformulation and preliminary formulation studies of mesalazine gastro-resistant tablets
by: Adriana Aurelia Chiş, et al.
Published: (2020-12-01)

Bipolymeric Pectin Millibeads Doped with Functional Polymers as Matrices for the Controlled and Targeted Release of Mesalazine
by: Dorota Wójcik-Pastuszka, et al.
Published: (2020-12-01)

Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis
by: Hong Shen, et al.
Published: (2021-07-01)

Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients
by: Shuying Li, et al.
Published: (2021-08-01)

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
by: C. J. J. Mulder, et al.
Published: (1998-01-01)